中国上海的医学专家团队近日研发出一系列新型显像探针，这些探针对肾透明细胞癌的诊断具有高特异性，有望显著提升该类型肾癌的精准治疗效果。肾透明细胞癌是肾癌中最常见的病理类型，但临床上缺乏高特异性的分子影像探针，导致诊断和治疗面临挑战。
据中新网报道，上海交通大学医学院附属仁济医院泌尿科郑军华、翟炜团队，核医学科刘建军、魏伟军团队与复旦大学附属华山医院核医学科谢芳团队联合取得了突破性成果。他们创新性地筛选并制备了一系列新型CD70特异性单域抗体免疫PET显像探针，能够有效识别肾透明细胞癌中的CD70表达，提高诊断的准确性。
CD70是一种肿瘤坏死因子超家族成员，在肾透明细胞癌中的阳性率超过85%，而在正常肾脏中没有表达，因此成为研发肾癌特异性探针的理想靶点。新型显像探针能够有效区分癌细胞和正常组织，对于早期发现肾癌复发或转移具有重要意义。
这项研究发表在核医学领域和泌尿外科领域的知名期刊上，显示出其研究成果的权威性和影响力。新型显像探针的研发成功，为肾透明细胞癌的精准诊断提供了新的工具，有望在未来临床实践中发挥重要作用，为患者带来更好的治疗效果。
英语如下：
News Title: “Chinese Experts Develop Novel Imaging Probes for Accurate Diagnosis of Renal Cell Carcinoma”
Keywords: Renal Cell Carcinoma, Imaging Probe, Accurate Diagnosis
News Content: A medical expert team from Shanghai has recently developed a series of novel imaging probes that have high specificity for the diagnosis of clear cell renal carcinoma, promising to significantly enhance the precision of treatment for this type of kidney cancer. Clear cell renal carcinoma is the most common pathological type of kidney cancer, but clinical diagnosis and treatment face challenges due to the lack of high-specificity molecular imaging probes.
According to Xinhua News Agency, the team led by Zheng Junhua and Zhai Wei from the Urology Department of Renji Hospital, affiliated to Shanghai Jiao Tong University School of Medicine, and the Nuclear Medicine Department of Fudan University Affiliated Huashan Hospital, has made breakthrough achievements. They have innovatively screened and prepared a series of novel CD70-specific single-domain antibody immuno-PET imaging probes, which can effectively identify CD70 expression in clear cell renal carcinoma, improving the accuracy of diagnosis.
CD70 is a member of the tumor necrosis factor superfamily, with a positivity rate exceeding 85% in clear cell renal carcinoma and no expression in normal kidneys, making it an ideal target for developing kidney cancer-specific probes. The novel imaging probes can effectively distinguish between cancer cells and normal tissues, and are of great significance for early detection of recurrence or metastasis of renal cancer.
This research has been published in renowned journals in the field of nuclear medicine and urology, demonstrating the authoritative and influential nature of their findings. The successful development of the novel imaging probes provides a new tool for the accurate diagnosis of clear cell renal carcinoma, and is expected to play a significant role in future clinical practice, bringing better treatment outcomes to patients.
【来源】http://www.chinanews.com/sh/2024/08-12/10267864.shtml
Views: 1